| Dr Patrick Francis Odonnell, DO | |
|
1 Healthcare Dr, Philippi, WV 26416 | |
| (304) 457-1760 | |
| Not Available |
| Full Name | Dr Patrick Francis Odonnell |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 1 Healthcare Dr, Philippi, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518288612 | NPI | - | NPPES |
| 3810027073 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2773 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Broaddus Hospital Association, Inc | Philippi, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Broaddus Hospital Association Inc | 5991692832 | 12 |
News Archive
"Unionized workers have fought to preserve their relatively expensive health plans through contract talks, sometimes at the expense of wage increases," CQ Politics reports. "Now, with some unions airing televised ads targeting senators who support the idea of counting some health benefits as taxable income, pressure is increasing on Capitol Hill to look elsewhere to offset the cost of a health care overhaul."
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
More than 2,000 people have died of cholera in Haiti since late October, Haitian officials said on Monday, the Associated Press/Washington Post reports (12/6). According to Haitian health ministry figures, a total of "2,013 people have died from the water-borne bacterial infection and 88,789 cases have been recorded," Agence France-Presse writes (12/6).
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
› Verified 5 days ago
| Entity Name | Broaddus Hospital Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548246622 PECOS PAC ID: 5991692832 Enrollment ID: O20040413001625 |
News Archive
"Unionized workers have fought to preserve their relatively expensive health plans through contract talks, sometimes at the expense of wage increases," CQ Politics reports. "Now, with some unions airing televised ads targeting senators who support the idea of counting some health benefits as taxable income, pressure is increasing on Capitol Hill to look elsewhere to offset the cost of a health care overhaul."
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
More than 2,000 people have died of cholera in Haiti since late October, Haitian officials said on Monday, the Associated Press/Washington Post reports (12/6). According to Haitian health ministry figures, a total of "2,013 people have died from the water-borne bacterial infection and 88,789 cases have been recorded," Agence France-Presse writes (12/6).
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick Francis Odonnell, DO 1 Healthcare Dr, Philippi, WV 26416-9405 Ph: (304) 457-1760 | Dr Patrick Francis Odonnell, DO 1 Healthcare Dr, Philippi, WV 26416 Ph: (304) 457-1760 |
News Archive
"Unionized workers have fought to preserve their relatively expensive health plans through contract talks, sometimes at the expense of wage increases," CQ Politics reports. "Now, with some unions airing televised ads targeting senators who support the idea of counting some health benefits as taxable income, pressure is increasing on Capitol Hill to look elsewhere to offset the cost of a health care overhaul."
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
More than 2,000 people have died of cholera in Haiti since late October, Haitian officials said on Monday, the Associated Press/Washington Post reports (12/6). According to Haitian health ministry figures, a total of "2,013 people have died from the water-borne bacterial infection and 88,789 cases have been recorded," Agence France-Presse writes (12/6).
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
› Verified 5 days ago
Randall Lee Turner, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Healthcare Dr, Philippi, WV 26416 Phone: 304-457-1760 | |
Dr. Robert B Sutherland, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Healthcare Dr, Philippi, WV 26416 Phone: 304-457-1760 Fax: 043-457-1516 |